Jpmorgan Chase & CO Actinium Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 21,124 shares of ATNM stock, worth $33,587. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,124
Previous 123,831
82.94%
Holding current value
$33,587
Previous $156,000
78.21%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ATNM
# of Institutions
64Shares Held
7.01MCall Options Held
39.2KPut Options Held
0-
Black Rock Inc. New York, NY1.88MShares$2.98 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.37MShares$2.18 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny663KShares$1.05 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA492KShares$782,1890.0% of portfolio
-
Geode Capital Management, LLC Boston, MA330KShares$524,2050.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $40M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...